What is the Fiscal Year for Enlivex?
Date: November 13, 2026
Enlivex's current fiscal year starts on January 1, 2026, and ends on December 31, 2026. Their current quarter is Q4, which ends on December 31, 2026.
Current Fiscal Year Overview
Fiscal Year Start
January 1, 2026
Fiscal Year End
December 31, 2026
Current Quarter
Q4
Current Quarter End
December 31, 2026
Quarterly Breakdown
Q1
Jan 1, 2026 – Mar 31, 2026
Q2
Apr 1, 2026 – Jun 30, 2026
Q3
Jul 1, 2026 – Sep 30, 2026
Q4
Oct 1, 2026 – Dec 31, 2026
Company Information
Headquarters
Nes-Ziona, Israel
Industry
Biotechnology Research
Stock Symbol
ENLV
Website
https://enlivex.comDescription
Enlivex (NASDAQ: $ENLV) is The Quality Longevity Company, combining a clinical biotechnology platform with a prediction markets treasury strategy. The company’s clinical engine is Allocetra™, an immunotherapy in development for aging-related diseases, initially focused on knee osteoarthritis. Alongside its clinical program, Enlivex operates a prediction markets treasury via the Rain Protocol, creating a scalable capital engine designed to support the long-term development of new therapies.
Use Salesmotion for Account Data and Insights
Sales professionals can use Salesmotion to access comprehensive account intelligence and automate their research. Instantly get insights on companies like Enlivex and uncover key business information that drives smarter conversations.
Book a demo today to strengthen your sales strategy with powerful data and actionable insights.